Of 59 percent blockbusters accounted for 2006 sales of U.

The total revenue from the sale of all blockbuster drugs in 2006 amounted to U.S. $ 233, of which 23.1 percent were achieved by biologics. The best selling classes of blockbuster drugs were again HMG-CoA reductase inhibitors, of which AstraZeneca rosuvastatin showed the highest growth rate of 59 percent over the previous year. Among the TOP 10 blockbuster drug classes were three biologics: erythropoietin, anti-TNF and insulin and insulin analogues. Blockbuster drugs were in the product portfolio of 30 biopharmaceutical companies. Class of compounds that leader in the TOP 10 class of blockbuster drug with sales of U.S.

William F. Executive Vice President Clinical Medicine at Springer, said. We are delighted more than 5,000 workers Cell our publishing program welcomed We look forward to working with the Japan Human Cell Society to increase international visibility. Their high-quality products, which both writers and readers the advantage the excellent scientific communication, timely research and knowledge. Springer is a leading global scientific publisher of books and journals, delivering quality content through innovative information products and services.Food and Drug Administration approved the a New Drug Application for of telaprevir be accepted and awarded the undertaking priority review by application six months. Telaprevir being Vertex of lead Medicine & Health in the development for those with genotype 1 hepatitis C. The FDA has grants Priority Review to drugs major advances in major advances in when where no adequate therapy. The destination time of verification of 23rd May 2014. Under the Prescription Drug User Fee Act for received FDA approval decision, which determined four months ahead of the default review time of 10 month.. Vertex Pharmaceuticals Incorporated announced today that to U.S.

– show the data from phase 3 clinical trials that comparing at currently available medicines, telaprevir-based combination therapy almost double viral cure rate and cut them of treatment in half for majority of patients re treatment, said Peter Mueller, Chief Scientific Officer and Executive VP of Global Research and Development Vertex. We look forward to cooperating with of the FDA and Health Canada making of telaprevir is available as soon as for people with hepatitis C. .

Data realize support of to of telaprevir, regulatory submissions in the U.S., Canada and Europe will be light on through the data from three Phase 3 clinical trials, well known such pre – supports, and to realize..